metastases given androgen deprivation therapy . J Urol 2002 ; 167 : 2361 – 2367 ; discussion 2367 . 133 Smith MR McGovern FJ Zietman AL . Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for
Search Results
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak
Matthew Zibelman and Anthony J. Olszanski
months after initial dose of ipilimumab reveals a marked decrease in size and fludeoxyglucose-avidity of right neck mass and complete resolution of bilateral adrenal and liver metastases (representative images). Discussion This case
Kelly G. Paulson and Shailender Bhatia
is aggressive, and approximately 37% of patients have nodal or distant spread at presentation ( Figure 1B ); sentinel lymph node evaluation is thus frequently useful to identify subclinical nodal metastases. 4 , 6 Systemic radiologic staging is
Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt
were the most commonly used means of screening for metastases. The HRS was recorded for 17.5% of all women and for 27.5% of traced patients. Therapy Characteristics Therapy Received and Guideline Adherence In the population-based cohort, there
Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt
were the most commonly used means of screening for metastases. The HRS was recorded for 17.5% of all women and for 27.5% of traced patients. Therapy Characteristics Therapy Received and Guideline Adherence In the population-based cohort, there
Anisley Valenciaga, O. Hans Iwenofu, and Gabriel Tinoco
liver metastases seen in (A) right posterior hepatic lobe measuring 1.9 cm and (B) right inferior lobe measuring 1.1 cm (yellow arrows) while patient received olaratumab maintenance therapy 15 months after initial surgery. The patient was then
Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano
nodal metastases and distant metastases, and greater accuracy versus bone scan in the detection of bone metastases. 4 – 6 One retrospective study by Niikura et al 7 reported 97.4% sensitivity and 91.2% specificity for PET/CT imaging compared with 85
Anthony J. Olszanski
're looking at patients with melanoma because it can upstage them.” “N” refers to the number of tumor-involved regional lymph nodes and presence of in-transit, satellite, or microsatellite metastases. These can be clinically detected (ie, identified by
Boshen Jiao, Yaw A. Nyame, Josh J. Carlson, Louis P. Garrison Jr, and Anirban Basu
diagnosis of metastatic disease), 23 and presence of visceral or bone metastases. Statistical Analysis Primary Analysis We conducted a retrospective difference-in-differences (DID) analysis to assess the differential utilization of AAP between
Louis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, Joachim Baehring, Henry Brem, Steven Brem, Nicholas Butowski, Jian L. Campian, Stephen W. Clark, Andrew J. Fabiano, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Craig Horbinski, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, Ian Robins, Jason Rockhill, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Lode J. Swinnen, Stephanie Weiss, Patrick Yung Wen, Nicole E. Willmarth, Mary Anne Bergman, and Susan D. Darlow
one or many brain metastases, and they may have a malignancy that is highly responsive or, alternatively, highly resistant to radiation therapy (RT) or chemotherapy. Because of this marked heterogeneity, the prognostic features and treatment options
